TipRanks
Advertisement
Advertisement
Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
PremiumThe FlyLakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
2M ago
Is LKFT a Buy, Before Earnings?
Premium
Pre-Earnings
Is LKFT a Buy, Before Earnings?
2M ago
Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program
Premium
Company Announcements
Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program
3M ago
Lakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program
PremiumCompany AnnouncementsLakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program
3M ago
Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners
Premium
Company Announcements
Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners
3M ago
Lakefront Biotherapeutics Buys Back 77,667 Shares Under June 2026 Repurchase Program
Premium
Company Announcements
Lakefront Biotherapeutics Buys Back 77,667 Shares Under June 2026 Repurchase Program
3M ago
Lakefront Biotherapeutics Discloses Bank of America Building 9.3% Stake
PremiumCompany AnnouncementsLakefront Biotherapeutics Discloses Bank of America Building 9.3% Stake
4M ago
Lakefront Biotherapeutics Bets Big on Ouro Pivot
Premium
Company Announcements
Lakefront Biotherapeutics Bets Big on Ouro Pivot
5M ago
Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline
Premium
Company Announcements
Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―